Table 3.

Results of univariate survival analyses

Factor	Threshold/criterion	PFS		OS
		P value	Survival time	P value	Survival time
Age	< 70 vs. > 70 years	0.552	12 vs. 9 months	0.108	22 vs. 17 months
Resection	CR vs. B/PR	0.038	13 vs. 10 months	0.121	23 vs. 15 months
IDH mutation	mutant vs. wildtype	< 0.001	33 vs. 9 months	< 0.001	54 vs. 13 months
MGMT promoter	methylated vs. non-methylated	< 0.001	18 vs. 7 months	< 0.001	29 vs. 12 months
KPS	100% vs. < 100%	0.143	14 vs. 9 months	0.015	29 vs. 13 months
TBRmax	< 2.55 vs. > 2.55	0.072	12 vs. 7 months	0.004	24 vs. 12 months
TBRmean	< 2.05 vs. > 2.05	0.112	14 vs. 7 months	0.038	25 vs. 12 months
TTP	< 25 vs. > 25 min	0.005	13 vs. 7 months	< 0.001	29 vs. 12 months
Slope	> − 0.103 vs. < − 0.103 SUV/h	0.065	9 vs. 6 months	0.021	17 vs. 9 months
MTV	11.15 mL	0.406	12 vs. 7 months	0.048	24 vs. 12 months

B biopsy, CR complete resection, IDH isocitrate dehydrogenase, KPS Karnofsky Performance Score, MGMT, O⁶-methylguanine-DNA-methyltransferase, MTV, metabolic tumour volume, OS overall survival, PFS progression-free survival, PR partial resection, TBR_max maximum tumour-to-brain ratio of FET uptake, TBR_mean mean tumour-to-brain ratio of FET uptake, SUV standardized uptake value